INTRA-ARTICULAR INJECTION OF HYDROLYZED COLLAGEN TO TREAT SYMPTOMS OF KNEE OSTEOARTHRITIS. A FUNCTIONAL IN VITRO INVESTIGATION AND A PILOT RETROSPECTIVE CLINICAL STUD

A novel Hydrolized collagen formulation to treat symptoms in knee osteoarthritis

Among all joints affected, knee osteoarthritis has a prevalence of about 10% in men and 13% in women over 60 years old. The primary objective of this study was to investigate the in vitro and in vivo effects of ChondroGrid in treating knee osteoarthritis symptoms to assess its safety and performance. . Records of 20 patients affected by Kellgren Lawrence grade 1 to 4 knee osteoarthritis who received three 4mg/2mL ChondroGrid injections 2 weeks apart were then retrospectively assessed to compare VAS, Lequesne, and WOMAC scores collected before and 15, 45, and 225 days after the first injection. ChondroGrid had no effects on the markers under consideration, but induced type-II and inhibited type-I collagen deposition; the Bern score was higher when cells were cultured with ChondroGrid. Patients experienced a 44% Lequesne score and a 55% VAS at moving score reduction. All other scores decreased >70%. ChondroGrid may prompt chondrocytes to produce hyaline cartilage, prevent fibrous tissue formation, and be a safe and effective adjuvant to treat symptomatic knee.

PRODUCTS USED: CHondroGrid CHG-004 CHG-PK4